Industry Research Reports
Global Diabetes Therapeutics and Diagnostics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Industry: Medical Care
Published Date: 2025-09-06
Pages: 120 Pages
Report ld: 4991867
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Diabetes Therapeutics and Diagnostics Market Size(US$)
CAGR 2025-2031
2.5%
Market Size,2031
USD 150,030
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Diabetes Therapeutics and Diagnostics market size was US$ 126520 million in 2024 and is forecast to a readjusted size of US$ 150030 million by 2031 with a CAGR of 2.5% during the forecast period 2025-2031.
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Diabetes Therapeutics and Diagnostics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
MARKET SEGMENTATION
By Company
- 77 Elektronika Kft.
- A. Menarini Diagnostics S.R.L
- Abbott Laboratories
- Agamatrix Inc.
- Animas Corp.
- Ascensia
- Becton Dickinson
- Debiotech S.A.
- Eli Lilly And Co.
- Glaxo Smithkline
- Inlight Solutions Inc.
- Johnson & Johnson
- Lifescan Inc.
- Medtronic
- Merck & Co.
- Merck KGAA
- Nipro Corp.
- Novartis Pharma Ag
- Novo Nordisk A/S
- Owen Mumford Ltd.
- Palco Labs Inc.
- Roche
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
- Terumo Corp.
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Drugs
- Diagnosis And Monitoring
- Others
Segment by Application
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Others
CHAPTER OUTLINE
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Diabetes Therapeutics and Diagnostics market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Insulin Delivery in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Type 2 Diabetes in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Diabetes Therapeutics and Diagnostics value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Insulin
1.2.3 Insulin Delivery
1.2.4 Oral Hypoglycemic Drugs
1.2.5 Diagnosis And Monitoring
1.2.6 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.3.4 Gestational Diabetes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetes Therapeutics and Diagnostics Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Diabetes Therapeutics and Diagnostics Revenue Market Share by Region (2020-2025)
2.4 Global Diabetes Therapeutics and Diagnostics Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
2.5.2 Europe Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
2.5.3 China Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
2.5.4 Japan Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
2.5.6 India Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
2.5.7 Central & South America Diabetes Therapeutics and Diagnostics Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Diabetes Therapeutics and Diagnostics Historic Market Size by Type (2020-2025)
3.2 Global Diabetes Therapeutics and Diagnostics Forecasted Market Size by Type (2026-2031)
3.3 Different Types Diabetes Therapeutics and Diagnostics Representative Players
4 Breakdown Data by Application
4.1 Global Diabetes Therapeutics and Diagnostics Historic Market Size by Application (2020-2025)
4.2 Global Diabetes Therapeutics and Diagnostics Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Diabetes Therapeutics and Diagnostics Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Diabetes Therapeutics and Diagnostics Players by Revenue (2020-2025)
5.1.2 Global Diabetes Therapeutics and Diagnostics Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Diabetes Therapeutics and Diagnostics Revenue
5.4 Global Diabetes Therapeutics and Diagnostics Market Concentration Analysis
5.4.1 Global Diabetes Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Diabetes Therapeutics and Diagnostics Revenue in 2024
5.5 Global Key Players of Diabetes Therapeutics and Diagnostics Head office and Area Served
5.6 Global Key Players of Diabetes Therapeutics and Diagnostics, Product and Application
5.7 Global Key Players of Diabetes Therapeutics and Diagnostics, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Diabetes Therapeutics and Diagnostics Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Diabetes Therapeutics and Diagnostics Market Size by Type (2020-2025)
6.1.2.2 North America Diabetes Therapeutics and Diagnostics Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Diabetes Therapeutics and Diagnostics Market Size by Application (2020-2025)
6.1.3.2 North America Diabetes Therapeutics and Diagnostics Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Diabetes Therapeutics and Diagnostics Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Diabetes Therapeutics and Diagnostics Market Size by Type (2020-2025)
6.2.2.2 Europe Diabetes Therapeutics and Diagnostics Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Diabetes Therapeutics and Diagnostics Market Size by Application (2020-2025)
6.2.3.2 Europe Diabetes Therapeutics and Diagnostics Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Diabetes Therapeutics and Diagnostics Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Diabetes Therapeutics and Diagnostics Market Size by Type (2020-2025)
6.3.2.2 China Diabetes Therapeutics and Diagnostics Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Diabetes Therapeutics and Diagnostics Market Size by Application (2020-2025)
6.3.3.2 China Diabetes Therapeutics and Diagnostics Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Diabetes Therapeutics and Diagnostics Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Diabetes Therapeutics and Diagnostics Market Size by Type (2020-2025)
6.4.2.2 Japan Diabetes Therapeutics and Diagnostics Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Diabetes Therapeutics and Diagnostics Market Size by Application (2020-2025)
6.4.3.2 Japan Diabetes Therapeutics and Diagnostics Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Diabetes Therapeutics and Diagnostics Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Diabetes Therapeutics and Diagnostics Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Diabetes Therapeutics and Diagnostics Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Diabetes Therapeutics and Diagnostics Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Diabetes Therapeutics and Diagnostics Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Diabetes Therapeutics and Diagnostics Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Diabetes Therapeutics and Diagnostics Market Size by Type (2020-2025)
6.6.2.2 India Diabetes Therapeutics and Diagnostics Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Diabetes Therapeutics and Diagnostics Market Size by Application (2020-2025)
6.6.3.2 India Diabetes Therapeutics and Diagnostics Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 77 Elektronika Kft.
7.1.1 77 Elektronika Kft. Company Details
7.1.2 77 Elektronika Kft. Business Overview
7.1.3 77 Elektronika Kft. Diabetes Therapeutics and Diagnostics Introduction
7.1.4 77 Elektronika Kft. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.1.5 77 Elektronika Kft. Recent Development
7.2 A. Menarini Diagnostics S.R.L
7.2.1 A. Menarini Diagnostics S.R.L Company Details
7.2.2 A. Menarini Diagnostics S.R.L Business Overview
7.2.3 A. Menarini Diagnostics S.R.L Diabetes Therapeutics and Diagnostics Introduction
7.2.4 A. Menarini Diagnostics S.R.L Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.2.5 A. Menarini Diagnostics S.R.L Recent Development
7.3 Abbott Laboratories
7.3.1 Abbott Laboratories Company Details
7.3.2 Abbott Laboratories Business Overview
7.3.3 Abbott Laboratories Diabetes Therapeutics and Diagnostics Introduction
7.3.4 Abbott Laboratories Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.3.5 Abbott Laboratories Recent Development
7.4 Agamatrix Inc.
7.4.1 Agamatrix Inc. Company Details
7.4.2 Agamatrix Inc. Business Overview
7.4.3 Agamatrix Inc. Diabetes Therapeutics and Diagnostics Introduction
7.4.4 Agamatrix Inc. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.4.5 Agamatrix Inc. Recent Development
7.5 Animas Corp.
7.5.1 Animas Corp. Company Details
7.5.2 Animas Corp. Business Overview
7.5.3 Animas Corp. Diabetes Therapeutics and Diagnostics Introduction
7.5.4 Animas Corp. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.5.5 Animas Corp. Recent Development
7.6 Ascensia
7.6.1 Ascensia Company Details
7.6.2 Ascensia Business Overview
7.6.3 Ascensia Diabetes Therapeutics and Diagnostics Introduction
7.6.4 Ascensia Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.6.5 Ascensia Recent Development
7.7 Becton Dickinson
7.7.1 Becton Dickinson Company Details
7.7.2 Becton Dickinson Business Overview
7.7.3 Becton Dickinson Diabetes Therapeutics and Diagnostics Introduction
7.7.4 Becton Dickinson Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.7.5 Becton Dickinson Recent Development
7.8 Debiotech S.A.
7.8.1 Debiotech S.A. Company Details
7.8.2 Debiotech S.A. Business Overview
7.8.3 Debiotech S.A. Diabetes Therapeutics and Diagnostics Introduction
7.8.4 Debiotech S.A. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.8.5 Debiotech S.A. Recent Development
7.9 Eli Lilly And Co.
7.9.1 Eli Lilly And Co. Company Details
7.9.2 Eli Lilly And Co. Business Overview
7.9.3 Eli Lilly And Co. Diabetes Therapeutics and Diagnostics Introduction
7.9.4 Eli Lilly And Co. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.9.5 Eli Lilly And Co. Recent Development
7.10 Glaxo Smithkline
7.10.1 Glaxo Smithkline Company Details
7.10.2 Glaxo Smithkline Business Overview
7.10.3 Glaxo Smithkline Diabetes Therapeutics and Diagnostics Introduction
7.10.4 Glaxo Smithkline Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.10.5 Glaxo Smithkline Recent Development
7.11 Inlight Solutions Inc.
7.11.1 Inlight Solutions Inc. Company Details
7.11.2 Inlight Solutions Inc. Business Overview
7.11.3 Inlight Solutions Inc. Diabetes Therapeutics and Diagnostics Introduction
7.11.4 Inlight Solutions Inc. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.11.5 Inlight Solutions Inc. Recent Development
7.12 Johnson & Johnson
7.12.1 Johnson & Johnson Company Details
7.12.2 Johnson & Johnson Business Overview
7.12.3 Johnson & Johnson Diabetes Therapeutics and Diagnostics Introduction
7.12.4 Johnson & Johnson Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.12.5 Johnson & Johnson Recent Development
7.13 Lifescan Inc.
7.13.1 Lifescan Inc. Company Details
7.13.2 Lifescan Inc. Business Overview
7.13.3 Lifescan Inc. Diabetes Therapeutics and Diagnostics Introduction
7.13.4 Lifescan Inc. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.13.5 Lifescan Inc. Recent Development
7.14 Medtronic
7.14.1 Medtronic Company Details
7.14.2 Medtronic Business Overview
7.14.3 Medtronic Diabetes Therapeutics and Diagnostics Introduction
7.14.4 Medtronic Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.14.5 Medtronic Recent Development
7.15 Merck & Co.
7.15.1 Merck & Co. Company Details
7.15.2 Merck & Co. Business Overview
7.15.3 Merck & Co. Diabetes Therapeutics and Diagnostics Introduction
7.15.4 Merck & Co. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.15.5 Merck & Co. Recent Development
7.16 Merck KGAA
7.16.1 Merck KGAA Company Details
7.16.2 Merck KGAA Business Overview
7.16.3 Merck KGAA Diabetes Therapeutics and Diagnostics Introduction
7.16.4 Merck KGAA Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.16.5 Merck KGAA Recent Development
7.17 Nipro Corp.
7.17.1 Nipro Corp. Company Details
7.17.2 Nipro Corp. Business Overview
7.17.3 Nipro Corp. Diabetes Therapeutics and Diagnostics Introduction
7.17.4 Nipro Corp. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.17.5 Nipro Corp. Recent Development
7.18 Novartis Pharma Ag
7.18.1 Novartis Pharma Ag Company Details
7.18.2 Novartis Pharma Ag Business Overview
7.18.3 Novartis Pharma Ag Diabetes Therapeutics and Diagnostics Introduction
7.18.4 Novartis Pharma Ag Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.18.5 Novartis Pharma Ag Recent Development
7.19 Novo Nordisk A/S
7.19.1 Novo Nordisk A/S Company Details
7.19.2 Novo Nordisk A/S Business Overview
7.19.3 Novo Nordisk A/S Diabetes Therapeutics and Diagnostics Introduction
7.19.4 Novo Nordisk A/S Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.19.5 Novo Nordisk A/S Recent Development
7.20 Owen Mumford Ltd.
7.20.1 Owen Mumford Ltd. Company Details
7.20.2 Owen Mumford Ltd. Business Overview
7.20.3 Owen Mumford Ltd. Diabetes Therapeutics and Diagnostics Introduction
7.20.4 Owen Mumford Ltd. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.20.5 Owen Mumford Ltd. Recent Development
7.21 Palco Labs Inc.
7.21.1 Palco Labs Inc. Company Details
7.21.2 Palco Labs Inc. Business Overview
7.21.3 Palco Labs Inc. Diabetes Therapeutics and Diagnostics Introduction
7.21.4 Palco Labs Inc. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.21.5 Palco Labs Inc. Recent Development
7.22 Roche
7.22.1 Roche Company Details
7.22.2 Roche Business Overview
7.22.3 Roche Diabetes Therapeutics and Diagnostics Introduction
7.22.4 Roche Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.22.5 Roche Recent Development
7.23 Sanofi
7.23.1 Sanofi Company Details
7.23.2 Sanofi Business Overview
7.23.3 Sanofi Diabetes Therapeutics and Diagnostics Introduction
7.23.4 Sanofi Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.23.5 Sanofi Recent Development
7.24 Takeda Pharmaceutical Co. Ltd.
7.24.1 Takeda Pharmaceutical Co. Ltd. Company Details
7.24.2 Takeda Pharmaceutical Co. Ltd. Business Overview
7.24.3 Takeda Pharmaceutical Co. Ltd. Diabetes Therapeutics and Diagnostics Introduction
7.24.4 Takeda Pharmaceutical Co. Ltd. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.24.5 Takeda Pharmaceutical Co. Ltd. Recent Development
7.25 Terumo Corp.
7.25.1 Terumo Corp. Company Details
7.25.2 Terumo Corp. Business Overview
7.25.3 Terumo Corp. Diabetes Therapeutics and Diagnostics Introduction
7.25.4 Terumo Corp. Revenue in Diabetes Therapeutics and Diagnostics Business (2020-2025)
7.25.5 Terumo Corp. Recent Development
8 Diabetes Therapeutics and Diagnostics Market Dynamics
8.1 Diabetes Therapeutics and Diagnostics Industry Trends
8.2 Diabetes Therapeutics and Diagnostics Market Drivers
8.3 Diabetes Therapeutics and Diagnostics Market Challenges
8.4 Diabetes Therapeutics and Diagnostics Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Diabetes Therapeutics and Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Diabetes Therapeutics and Diagnostics was estimated to be worth US$ 129370 million in 2025 and is projected to reach US$ 153410 million, growing at a CAGR of 2.5% from 2026 to 2032.
Published Date: 2026-07-15
Pages: 152
USD 3950.00
(Single User License)
Global Diabetes Therapeutics and Diagnostics Market Research Report 2026
The global Diabetes Therapeutics and Diagnostics market was valued at US$ 129370 million in 2025 and is anticipated to reach US$ 153410 million by 2032, at a CAGR of 2.5% from 2026 to 2032.
Published Date: 2026-04-28
Pages: 144
USD 2900.00
(Single User License)
Diabetes Therapeutics and Diagnostics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Diabetes Therapeutics and Diagnostics was estimated to be worth US$ 126520 million in 2024 and is forecast to a readjusted size of US$ 150030 million by 2031 with a CAGR of 2.5% during the forecast period 2025-2031.
Published Date: 2025-02-27
Pages: 141
USD 3950.00
(Single User License)
Global Diabetes Therapeutics and Diagnostics Market Research Report 2025
The global market for Diabetes Therapeutics and Diagnostics was valued at US$ 126520 million in the year 2024 and is projected to reach a revised size of US$ 150030 million by 2031, growing at a CAGR of 2.5% during the forecast period.
Published Date: 2025-02-27
Pages: 108
USD 2900.00
(Single User License)
Global Diabetes Therapeutics and Diagnostics Market Insights, Forecast to 2030
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Published Date: 2024-04-15
Pages: 127
USD 4900.00
(Single User License)
Diabetes Therapeutics and Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Published Date: 2024-01-24
Pages: 166
USD 3950.00
(Single User License)
Global Diabetes Therapeutics and Diagnostics Market Research Report 2024
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Published Date: 2024-01-16
Pages: 108
USD 2900.00
(Single User License)
Diabetes Therapeutics and Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Diabetes Therapeutics and Diagnostics was estimated to be worth US$ 129370 million in 2025 and is projected to reach US$ 153410 million, growing at a CAGR of 2.5% from 2026 to 2032.
Published: 2026-07-15
Pages: 152
USD 3950.00 (Single User License)Global Diabetes Therapeutics and Diagnostics Market Research Report 2026
The global Diabetes Therapeutics and Diagnostics market was valued at US$ 129370 million in 2025 and is anticipated to reach US$ 153410 million by 2032, at a CAGR of 2.5% from 2026 to 2032.
Published: 2026-04-28
Pages: 144
USD 2900.00 (Single User License)Diabetes Therapeutics and Diagnostics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Diabetes Therapeutics and Diagnostics was estimated to be worth US$ 126520 million in 2024 and is forecast to a readjusted size of US$ 150030 million by 2031 with a CAGR of 2.5% during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 141
USD 3950.00 (Single User License)Global Diabetes Therapeutics and Diagnostics Market Research Report 2025
The global market for Diabetes Therapeutics and Diagnostics was valued at US$ 126520 million in the year 2024 and is projected to reach a revised size of US$ 150030 million by 2031, growing at a CAGR of 2.5% during the forecast period.
Published: 2025-02-27
Pages: 108
USD 2900.00 (Single User License)Global Diabetes Therapeutics and Diagnostics Market Insights, Forecast to 2030
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Published: 2024-04-15
Pages: 127
USD 4900.00 (Single User License)Diabetes Therapeutics and Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Published: 2024-01-24
Pages: 166
USD 3950.00 (Single User License)Global Diabetes Therapeutics and Diagnostics Market Research Report 2024
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Published: 2024-01-16
Pages: 108
USD 2900.00 (Single User License)
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now